Small Molecules

01 Feb 2017 Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue
01 Feb 2017 SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication
01 Feb 2017 Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
31 Jan 2017 Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
31 Jan 2017 Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
31 Jan 2017 Angion Biomedica Corp.’s Phase 2 “GUARD” Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft Function (DGF)
31 Jan 2017 Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase
31 Jan 2017 Endo Announces U.S. FDA Approval of Ephedrine Sulfate Injection, USP
31 Jan 2017 Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
31 Jan 2017 Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
30 Jan 2017 X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease
30 Jan 2017 Fostamatinib Study Results Continue to Trend Positive
30 Jan 2017 BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency
30 Jan 2017 FDA Approves Allergan's sNDA for AVYCAZ® (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis
30 Jan 2017 FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
30 Jan 2017 Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
30 Jan 2017 Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
30 Jan 2017 Sunovion’s Latuda® (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
27 Jan 2017 Kainos Medicine Announces Initiation of Phase 1 Clinical Study of KM-819 in the Treatment of Parkinson's Disease
27 Jan 2017 Novan Reports Topline Results from SB204 Phase 3 Pivotal Trials
27 Jan 2017 Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease
27 Jan 2017 Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis
27 Jan 2017 Celgene Receives Positive CHMP Opinion to Expand REVLIMID® (Lenalidomide) Indication as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma (MM) after Autologous Stem Cell Transplantation
26 Jan 2017 X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell Carcinoma
26 Jan 2017 U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing